Travere Therapeutics Reports Third Quarter 2026 Financial Results
Business Wire•02/11/2026•16:01 ET
0
Key Highlights
- ➤FILSPARI U.S. sales $200.2 million, up 120% year-over-year in Q3 2026
- ➤Q3 net loss $52.3 million, versus $25.7 million net income year earlier
- ➤1,932 new FILSPARI patient start forms received during Q3
- ➤HARMONY Phase 3 topline results remain on track for 2H 2027
- ➤Civorebrutinib U.S. IND submission planned by year-end
Expert Statements
Eric Dube, President and Chief Executive Officer of Travere Therapeutics
“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS. We remain early in reaching the more than 100,000 addressable patients across these conditions, reinforcing our confidence in FILSPARI’s substantial long-term opportunity. Alongside this commercial progress, we are advancing pegtibatinase toward pivotal Phase 3 results in the second half of next year and progressing civorebrutinib toward late-stage clinical development. As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline, and a shared commitment to delivering hope to patients.”
Travere Therapeutics Reports Third Quarter 2026 Financial Results
U.S. net product sales of FILSPARI® totaled $200 million, representing 120% growth year-over-year; 1,932 new PSFs received during the quarter
Get started
Create a free account to read the full story.